Newco Linkgevity Ltd. has won backing from the KQ Labs accelerator program at the Francis Crick Institute in London, enabling it to take forward the lead program, an anti-necrotic drug for treating acute kidney injury, and to further develop its AI-driven system for identifying aging-related therapeutic targets. Alongside access to the Crick’s expertise in translational research and in shaping academic science to make it investible, companies joining KQ Labs receive an equity investment.
Acute kidney injury (AKI) may progress to chronic kidney disease, and there is an urgent need for approaches that improve the limited regeneration of the renal tubules after AKI.
Newco Linkgevity Ltd. has won backing from the KQ Labs accelerator program at the Francis Crick Institute in London, enabling it to take forward the lead program, an anti-necrotic drug for treating acute kidney injury, and to further develop its AI-driven system for identifying aging-related therapeutic targets.
Researchers from Renmin Hospital of Wuhan University have assessed the role of ankyrin repeat domain 1 (ANKRD1) in renal ischemia-reperfusion injury (IRI), which is the primary cause of acute kidney injury (AKI).
Acute kidney injury (AKI) is a common disease with high morbidity that still lacks effective drug treatments. The death of tubular epithelial cells is the principal basis for AKI. This cell death in AKI does not occur by necrosis but by other cell death mechanisms such as pyroptosis, among others. Recent findings have implicated chromodomain Y-like (CDYL) in autosomal dominant polycystic kidney disease, but its role in AKI has not been established.
Seastar Medical Holding Corp. was granted a third breakthrough device designation by the U.S. FDA for its Selective Cytopheretic device (SCD), a biomimetic membrane-based device used to treat patients with acute inflammatory conditions, which can cause organ failure and death. The latest designation is for its use in patients with hepatorenal syndrome. It follows other indications including cardiorenal syndrome and in adults with acute kidney injury (AKI).
Researchers from Anhui Medical University (AMU) presented data from a study that aimed to assess the role of gastrin-releasing peptide (GRP) and its receptor GRPR in acute kidney injury (AKI).
Micurx Pharmaceuticals Inc. has patented peptide-drug conjugates consisting of peptide targeting kidney cells covalently linked to an anti-inflammatory or immunomodulating or nephron-protective drug through a linker reported to be useful for the treatment of acute kidney injury, chronic kidney disease, chronic glomerulonephritis, diabetic nephropathy and systemic lupus erythematosus, among others.
The U.S. FDA has cleared the way for Seastar Medical Holding Corp.. to conduct a pivotal IDE study of its Selective Cytopheretic Device (SCD) in adults with acute kidney injury (AKI). The Denver-based company plans to begin enrolling patients as early as next month.
Cardiorenal Systems Inc. has scored a U.S. FDA breakthrough device designation for technology to prevent patients undergoing cardiac surgery from developing acute kidney injury (AKI). AKI is reported in up to 30% of approximately 780,000 cardiac surgeries performed each year in the U.S., Europe and the Middle East, complicating patient recovery, prolonging ICU hospitalization and contributing to patient mortality after surgery.
